EGFR and ovarian carcinoma: A small study using ExoProfile, a novel immunocapture chip, instead identified a significant difference in EGFR expression on plasma-derived sEVs between patients with ovarian carcinoma and normal controls; however, the study only involved a small number (n = 15) of patients, so larger studies will be required to confirm the validity of this putative biomarker [223].